This consortium assembled in INOVPAIN gathers the complementary and synergic competences and reaches the critical mass necessary to achieve our objectives:

  • to define and characterize refractory chronic pain patients
  • to understand the mechanisms and favoring factors of treatmentresistance
  • to develop and diffuse new pain evaluation tools, new drugs and new neuromodulation solutions
  • to improve the management and education of refractory chronic pain.

This FHU project is a unique opportunity to gather such consortium around the topic of chronic pain in our territory, and would allow us to promote more ambitious nation-wide or European projects.

It brings together the expertise of 6 clinical teams and 8 research teams.

Hospital facilities

Hospital facilities are distributed across the 3 University Hospitals (two in Nice, one in Marseille), and the “Centre Anti-Cancéreux Antoine Lacassagne” (CAL).

Academic research teams

The research teams belong to the “Université Nice Sophia Antipolis” (UNS) recently re-organized in “University Cote d’Azur” (UCA) and are located either in Nice or in the Sophia Antipolis technopole and campus (IPMC, INRIA).

Platforms and core facilities

The clinical – research interface benefits from interactions with several platforms located in Nice and Sophia Antipolis, and especially with the new Pasteur 2 hospital neuroimaging platform and operating theater.

Teaching activities

The clinical and research partners of INOVPAIN are regularly involved in numerous local, regional and national medical and non-medical teaching activities.

Industrial collaborations

Industrial partners are involved in the Inovpain project.

Inovpain represents a unique opportunity to gather together these clinical teams experts in refractory chronic pain management, research teams experts in ion channels, pain transmission processes, modeling or psychology, and industrial partners, in a common objective: to develop innovative solutions in the domain of refractory chronic pain, which includes new evaluation tools, new pharmacologic therapies and new surgical neuromodulation treatments.